Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
7.93
+0.57 (7.74%)
At close: Aug 7, 2026, 4:00 PM EDT
7.93
0.00 (0.00%)
Pre-market: Aug 10, 2026, 6:23 AM EDT
Xeris Biopharma Holdings Employees
Xeris Biopharma Holdings had 435 employees as of December 31, 2025. The number of employees increased by 41 or 10.41% compared to the previous year.
Employees
435
Change (1Y)
41
Growth (1Y)
10.41%
Revenue / Employee
$771,067
Profits / Employee
-$39,460
Market Cap
1.45B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 435 | 41 | 10.41% |
| Dec 31, 2024 | 394 | 17 | 4.51% |
| Dec 31, 2023 | 377 | 22 | 6.20% |
| Dec 31, 2022 | 355 | 61 | 20.75% |
| Dec 31, 2021 | 294 | 114 | 63.33% |
| Sep 30, 2021 | 325 | 153 | 88.95% |
| Jun 30, 2021 | 253 | 65 | 34.57% |
| Mar 31, 2021 | 209 | 10 | 5.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| Phibro Animal Health | 2,475 |
| HUTCHMED (China) | 1,790 |
| Alvotech | 1,279 |
| ANI Pharmaceuticals | 970 |
| Pacira BioSciences | 829 |
| Cronos Group | 610 |
XERS News
- 3 days ago - Xeris Biopharma Holdings Earnings Call Transcript: Q2 2026 - Transcripts
- 3 days ago - Xeris Biopharma Holdings Earnings release: Q2 2026 - Filings
- 3 days ago - Xeris Biopharma Holdings Quarterly report: Q2 2026 - Filings
- 3 days ago - Xeris Biopharma tightens FY26 revnue view $385M-$390M, consensus $385.94M - TheFly
- 3 days ago - Xeris Biopharma Reports Second Quarter 2026 Financial Results - Business Wire
- 17 days ago - Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 - Business Wire
- 5 weeks ago - CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 5 weeks ago - Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire